{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'EMERGENCY CONTACTS', '24-hour emergency medical contact', '+1 512 652 0191 or', '+1 973 659 6677 or', '+3 318 699 0019', 'SAE reporting', 'All SAEs should be reported via the EDC', 'system by completing the relevant pages of', 'the eCRF.', 'In the event that the EDC system is not', 'functioning, SAEs must be reported to the', 'following email address:', 'QLS_Olokizumab@iqvia.com', 'Abbreviations: eCRF = electronic case report form; EDC = Electronic Data Capture; SAE = Serious Adverse', 'Event.', 'Amendment 2: 06 March 2019', '4', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'SYNOPSIS', 'Name of Sponsor', 'R-Pharm International', 'Name of Finished', 'Olokizumab', 'Product', 'Name of Active', 'Olokizumab (CDP6038; L04041)', 'Ingredient', 'Title of Study:', 'A Multicenter, Open-label, Phase III Study of the Efficacy and Safety of Olokizumab in', 'Subjects with Moderately to Severely Active Rheumatoid Arthritis', 'Protocol No:', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Investigators:', 'A total of approximately 250 Investigators will be involved in the conduct of this study.', 'Study sites:', 'The study will be conducted at approximately 250 sites across Russia, Belarus, the', 'United States (US), Europe, the United Kingdom, Asia, and Latin America.', 'Study duration:', 'Treatment Period: 82 weeks', 'Phase: III', 'Safety Follow-Up: 20 weeks', 'Objectives:', 'Primary:', 'The primary objective of this study is to evaluate the long-term safety and tolerability of olokizumab (OKZ)', '64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects', 'with moderately to severely active rheumatoid arthritis (RA) who previously completed 24 weeks of', 'double-blind treatment in Study CL04041022, CL04041023, or CL04041025 (core studies).', 'Secondary:', 'To evaluate the long-term efficacy of OKZ', 'To evaluate the long-term immunogenicity of OKZ', 'To evaluate the physical function and quality of life of subjects receiving long-term treatment with', 'OKZ', 'Criteria for Evaluation:', 'The following endpoints will be assessed to evaluate treatment with OKZ 64 mg administered SC q2w or q4w', 'for 106 total weeks for subjects randomized to OKZ in all 3 core studies (CL04041022, CL04041023, and', 'CL04041025), and for 82 total weeks for subjects randomized to placebo in the CL04041022 study and to', 'placebo or adalimumab in the CL04041023 core study. In Study CL04041025, subjects randomized to placebo', 'will transition to OKZ at Week 16 and complete 8 weeks of double-blind treatment with OKZ; these subjects', 'will complete 90 total weeks of treatment with OKZ.', 'Safety Endpoints:', 'The nature, incidence, severity, and outcome of adverse events (AEs), including serious adverse events', '(SAEs) and AEs of special interest (AESIs)', 'Follow-up-adjusted incidence and event rates (per 100 subject-years of follow-up) for SAEs and', 'AESIs', 'Proportions of subjects with clinically significant laboratory abnormalities', 'Assessment of changes over time in clinical laboratory parameters, vital sign measurements, and', 'physical examination findings', 'Time from first exposure to OKZ to the first occurrence of any major adverse cardiac event (MACE)', 'Incidence and titer of antidrug antibodies (ADAs) to OKZ, incidence of neutralizing antibodies, and', 'Amendment 2: 06 March 2019', '5', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'the time course of antibodies', 'Efficacy Endpoints:', 'Proportion of subjects achieving an American College of Rheumatology 20% (ACR20), American', 'College of Rheumatology 50% (ACR50), and American College of Rheumatology 70% (ACR70)', 'response who remain on randomized open-label treatment and in the study, assessed at all applicable', 'time points', 'Proportion of subjects with Simplified Disease Activity Index (SDAI) <3.3 remission, who remain on', 'randomized open-label treatment and in the study, assessed at all applicable time points', 'Proportion of subjects with Disease Activity Score 28-joint count (DAS28) low disease activity (based', 'on DAS28 C-reactive protein [CRP] <3.2), who remain on randomized open-label treatment and in the', 'study, assessed at all applicable time points', 'Change from baseline over time in DAS28 (CRP), assessed at all applicable time points', 'Change from baseline over time in the measure of physical ability based on Health Assessment', 'Questionnaire-Disability Index (HAQ-DI), assessed at all applicable time points', 'Proportion of subjects with improvement from baseline in HAQ-DI score 0.22, who remain on', 'randomized open-label treatment and in the study, assessed at all applicable time points', 'Change from baseline over time in the scores for the following patient-reported outcomes (PRO)', 'measures, assessed at all applicable time points:', '-', 'Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary', '(MCS) total scores', '-', 'European Quality of Life-5 Dimensions (EQ-5D)', '-', 'Work Productivity Survey-Rheumatoid Arthritis (WPS-RA)', '-', 'Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue)', 'Change from baseline over time in SDAI and Clinical Disease Activity Index (CDAI), assessed at all', 'applicable time points', 'Proportion of subjects with moderate to good responses for European League Against Rheumatism', '(EULAR) based on DAS28 (CRP), who remain on randomized open-label treatment and in the study,', 'assessed at all applicable time points, where a moderate response is defined as either DAS28 (CRP)', '5.1 with an improvement from baseline in DAS28 (CRP) >0.6 and 1.2, or DAS28 (CRP) >3.2 with', 'an improvement from baseline in DAS28 (CRP) >1.2, and a good response is defined as DAS28', '(CRP) <3.2 with an improvement from baseline in DAS28 (CRP) >1.2', 'Change from baseline to all time points in the components of the ACR response criteria', 'Immunogenicity:', 'Evaluating the impact of ADAs to OKZ on subject safety and efficacy', 'Methodology:', 'This OLE study (CL04041024) includes an 82-week open-label Treatment Period following completion of 1 of', 'the core studies (Study CL04041022, CL04041023, or CL04041025) from Visit 1 (OLE Baseline/Week 24) to', 'Visit 10 (End of Treatment [EoT]/Week 106), followed by a 20-week Safety Follow-Up Period from Week 106', 'to Week 126. The first visit of the OLE study is the same visit as the Week 24 visit in the core studies.', 'An estimated 1880 subjects will receive OKZ:', '1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w + methotrexate (MTX)', '2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX', 'Subjects will be randomized to 1 of the 2 OKZ treatment groups in the OLE study based on the treatment', 'received in the core studies. Subjects who received OKZ (q2w or q4w) in the core study in which they', 'participated (including subjects who received placebo in Study CL04041025 and were re-randomized to OKZ', 'Amendment 2: 06 March 2019', '6', 'Confidential']\n\n###\n\n", "completion": "END"}